国際学会
2007年
|
1. Nishiyama K, Sizuta S, Taniguchi R, Ehara N, Haruna Y, Abe M, Toma M, Furukawa Y, Kaburagi S, Doi O, Kambara H, Nara M, Matsuda K,
Hamasaki S, Tei C, Yamamoto H, Sakata R, Morimoto T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Chronic obstructive
pulmonary disease was an independent predictor of sudden cardiac death, cardiac death and all-cause mortality after percurtaneous
coronary intervention and coronary artery bypass grafting. J Am Coll Cardiol 2007;49(Suppl A):194A.
2. Shizuta S, Taniguchi R, Ehara N, Doi T, Nishiyama K, Furukawa Y, Tatami R, Ushijima T, Hattori R, Shirotani M, Nishiwaki N,
Tanaka M, Minami K, Sato Y, Tezuka S, Morimoto T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Comparison of percutaneous
coronary intervention and bypass surgery among patients with a chronic total occlusion and multi-vessel coronary artery disease
in the bare metal stent era. J Am Coll Cardiol 2007;49(Suppl A):229A.
3. Furukawa Y, Shizuta S, Haruna Y, Ehara N, Taniguchi R, Hoshino K, Tamura T, Kawanami M, Kadoya M, Matsuyama E, Miki S, Yoshida A,
Nakajima H, Sasae H, Morimoto T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Impact of pharmacologic management at discharge
for complicated risk factors on outcomes of diabetic patients undergoing first coronary revascularization: Perspectives from
CREDO-Kyoto registry. J Am Coll Cardiol 2007;49(Suppl A):348A.
4. Egawa H, Tanabe M, Shimazu M, Haga H, Tanaka K, Teramukai S, Fukushima M. ABO-Incompatible living donor liver transplantation:
Lessons from Japanese registry of 291 patients. Am J Transplant 2007;7:375, 886 Suppl 2.
5. Teramukai S, Nishimura T, Nakagawa M, Kawahara M, Kubota K, Furuse K, Fukushima M. Predictors and impacts of second-line
chemotherapy on survival after progression in patients with advanced non-small-cell lung cancer (NSCLC). Proc ASCO 2007;427s
(abstract #7675).
6. Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S, Williamson SK, Furuse K, McLeed HL, Mark PC. Pharmacogenomic
(PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing
population-related pharmacogenomics. Proc ASCO 2007;385s (abstract #7500).
7. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia
for drug efficacy in advanced gastric carcinoma: Analysis of prospective nationwide survey. Proc ASCO 2007;639s (abstract #15075).
8. Tada H, Tokoro R, Ishiwata R, Teramukai S, Fukushima M, Kubota K, Kawahara M, Furuse. Quality-of-life (QOL) evaluation for advanced
non-small cell lung cancer (NSCLC): Comparison between vinorelbine and gemcitabine followed by docetaxel (VGD), and paclitaxel and
carboplatin (PC) regimen on protocol JMTO LC00-03 (BRI LC03-01). Proc ASCO 2007;687s (abstract #18043).
9. Yamamoto K, Matsumoto S, Matsuba H, Tada H, Matsuyama A, Yanagihara K, Teramukai S, Fukushima M. Development of data capture
system for clinical study by the secondary use of electronic health records. MEDINFO 2007.8.
10. Teramukai S. Statistical comments on pharmacogenomic analysis. J Thor Oncol 2007;2(Suppl 4):S293 (WS-06-02).
11. Kawahara M, Tokoro R, Tada H, Ishiwata R, Teramukai S, Fukushima M, Kubota K, Shinkai T, Furuse K. Quality of life (QOL) evaluation
for advanced non-small cell lung cancer (NSCLC): a comparison between vinorelbine and gemcitabine followed by docetaxel (VGD), versus
paclitaxel and carboplatin (PC) regimen on a phase III protocol JMTO LC00-03 (BRI LC03-01). J Thorac Oncol 2007;2(Suppl 4):S839 (P1-253).
12. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe K, Nishiwaki Y, Ariyoshi Y, Williamson S, Gautschi
O, Lenz HJ, Mark PC, McLeod HL, Fukuoka M, Saijo N. Taxane-platinum pharmacogenomic predictors of outcomes in Japan-USA common arm
studies in advanced non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. J Thorac Oncol 2007;2
(Suppl 4):S172 (M08-01).
13. Gandara DR, Kawaguchi T, Crowley J, Furuse K, Kawahara M, Teramukai S, Williamson SK, Moon J, McLeed H, Mark PC. Updated paclitaxel-
carboplatin pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC). J
Thorac Oncol 2007;2(Suppl 4):S397 (D3-02).
14. Onodera R, Matsubara H, Teramukai S, Fukushima M. Clinical outcomes of revascularization treatment for lower limbs ischemia.
21世紀COEプログラム「融合的移植再生治療を目指す国際拠点形成」平成19年度国際シンポジウム 2007
15. Egawa H, Taira K, Teramukai S, Haga H, Fukushima M, Uemoto S. Recurrence of primary sclerosing cholangitis after living donor liver
transplantation. Transplant Int 2007;20(Suppl 2):15.
16. Teramukai S, Morita S. Bayesian predictive multi-stage design for phase II single-arm clinical trials: a case study. East Asia
Regional Biometrics Conference 2007 (EAR-BC ’07).
17. Morita S. Application of Bayesian approaches to early-phase clinical trials: Determining the effective sample size of a parametric
prior. East Asia Regional Biometric Conference 2007 (EAR-BC ‘07).
|
2006年
|
1. Haruna Y, Furukawa Y, Taniguchi R, Ehara N, Shizuta S, Mitsuoka H, Miura A, Kotoura H, Aota M, Kato H, Matsuyama E, Takahashi M, Tabata T, Miki I, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Anemia predicts long-term mortality and cardiovascular events in Japanese patients undergoing elective revascularization: From the coronary revascularization
demonstrating outcome study in Kyoto (CREDO-Kyoto). J Am Coll Cardiol 2006;47(Suppl. A):187A.
2. Ozasa N, Morimoto T, Shizuta S, Furukawa Y, Taniguchi R, Toma M, Haruna Y, Abe M, Nakagawa Y, Tamura T, Ehara N, Saito N, Doi T, Takizawa A, Shimamoto M, Murakami T, Yoshida A, Nakajima H, Matsui S, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Moderate
mitral regurgitation is associated with long-term prognosis in patients with coronary artery diseases undergone revascularization.
J Am Coll Cardiol 2006;47(Suppl. B):5B-6B.
3. Kimura T, Shizuta S, Ehara N, Taniguchi R, Haruna Y, Toma M, Tamura T, Abe M, Furukawa Y, Nakagawa Y, Nobuyoshi M, Okabayashi H, Mitsudo K, Komiya T, Ogawa H, Kawasuji M, Yoshida H, Takinami E, Imai Y, Teramukai S, Fukushima M, Komeda M, Kita T. Long-term
survival advantage of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in the real world
clinical practice: Is it real? J Am Coll Cardiol 2006;47(Suppl. B):7B.
4. Murayama T, Teramukai S, Nishimura H, Hatta T, Shimizu A, Fukushima M, Yokode M. Critical issues in Japanese translational
research. Clinical Trials 2006;3:213.
5. Zhou B, Teramukai S, Fukushima M. Prevention of alzheimer disease by statins- a meta analysis. Clinical Trials 2006;3:240.
6. Teramukai S, Ochiai K, Tada H, Fukushima M. A new prognostic index of advanced epithelial ovarian cancer (PIEPOC): A JMTO OC01-01 study. Proc ASCO 2006;24:270S (abstract #5061).
7. Nishizawa S, Inubushi M, Okada H, Ozawa F, Kojima S, Teramukai S, Fukushima M. Cancer screening trial to evaluate the efficacy of FDG-PET in healthy subjects ﾐ 2-year results of the Hamamatsu Medical Imaging Center study. Proc ASCO 2006;24:55S (abstract #1025).
8. Oba K, Teramukai S, Kobayashi M, Matsu T, Nakazato H, Ito K, Sakamoto J. Efficacy of adjuvant immunochemotherapy with
polysaccharide k (PSK) for patients with curatively resected gastric cancer. Proc ASCO 2006;24:627S (abstract #14038).
9. Kiba T Matsumoto S, Hatano E, Mori A, Yasumi S, Doi R, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Fukushima M. The
retrospective analysis of single agent gemcitabine for biliary tract cancers. Proc ASCO 2006;24:633S (abstract #14122).
10. Ichikawa M, Mio S, Teramukai S, Nakagawa M, Nagata Y, Fujita S, Yanagihara K, Ishiguro H, Hiraoka M, Mishima M. Clinical
outcomes of a multi-institutional retrospective study for 419 patients with locally advanced non-small cell lung cancer (NSCLC).
Proc ASCO 2006;24:671S (abstract #17058).
11. Suyama T, Taniguchi R, Haruna Y, Shizuta S, Tamura T, Toma M, Furukawa Y, Ehara N, Takashima H, Horie M, Higashita R, Asai T,
Doyama K, Fujino Y, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Impact of complete revascularization on long-term outcome
after percutaneous coronary intervention in the bare metal stent era: From the Coronary Revascularization Demonstrating Outcomes
in Kyoto (CREDO-Kyoto). Circulation 2006 (abstract #12669).
12. Haruna Y, Furukawa Y, Taniguchi R, Shizuta S, Imai M, Ehara N, Konishi T, Sugita T, Nishimura K, Matoba Y, Takahashi M,
Tabata T, Ishida K, Murakami T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T. Anemia predicts 2 years mortality and
cardiovascular events in Japanese patients undergoing first elective revascularization: from the Coronary Revascularization
Demonstrating Outcome study in Kyoto (CREDO-Kyoto). Circulation 2006 (abstract #15974).
13. Ozasa N, Taniguchi R, Abe M, Shizuta S, Haruna Y, Ehara N, Furukawa Y, Nakano A, Lee JD, Morioka K, Tanaka K, Takahashi M,
Oda T, Minematsu S, Imai Y, Teramukai S, Fukushima M, Morimot T, Kita T, Kimura T. Anemia predicts 2 years mortality and
cardiovascular events in Japanese patients undergoing first elective revascularization: from the Coronary Revascularization
Demonstrating Outcome study in Kyoto (CREDO-Kyoto). Circulation 2006 (abstract #15974).
14. Igarashi M, Ishikawa Y, Fujita T, Kawamori R, Teramoto T, Miyazaki S, Teramukai S. The study design of olmesartan mega study
to determine the relationship between cardiovascular events and blood pressure control in hypertensive patients in Japan
(OMEGA study). J Hypertens 2006; 24(Suppl 6): 296.
15. Yasuda H, Yanagihara K. Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions
of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma. AACR Meeting Abstracts, Sep
2006; 2006: B61
|
2005年
|
1. Kojima S, Inubushi M, Ozawa F, Okada H, Tanaka M, Fukunaga Y, Oda E, Teramukai S, Fukushima M, Nishizawa S.
Cancer screening trial using whole-body 18F-FDG PET scan in healthy subjects − the Hamamatsu Medical Imaging Center study.
Proc ASCO 2005;23:111s (abstract #1022).
2. Nakagawa M, Teramukai S, Tada H, Furuse K, Tanaka F, Mio T, Mishima M, Wada H, Fukushima M. Hypoalbuminemia as a risk factor
of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC) (JMTO LC03-02).
Proc ASCO 2005;23:667s (abstract #7190).
3. Teramukai S, Oda E, Nishiyama H, Fukushima M. Evaluation for surrogacy of endpoints by using data from observational studies:
a case-study in invasive bladder cancer. Clinical Trials 2005;2(Suppl):.S60-S61.
4. Teramukai S. Bayesian sequential design in translational research. 3rd US-Japan Biostatistics Workshop (Kyoto). 2005.10.
5. Ehara N, Taniguchi R, Morioka S, Shizuta S, Tamura T, Nishiyama K, Furukawa Y, Nobuyoshi M, Konishi T, Nishimura K, Kinoshita M,
Shiratori K, Teramukai S, Fukushima M, Komeda M, Kihara M, Kita T, Kimura T, for the CREDO-Kyoto Investigators. Comparison of
percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) in patients with multi-vessel coronary
artery disease (MVD) in the bare-metal stent (BMS) era: From the Coronary REvascularization Demonstrating Outcome study in Kyoto
(CREDO-Kyoto). Proc AHA 2005.
|
2004年
|
1. Kojima S, Hara A, Kosaka N, Matsuo Y, Suzuki H, Torigoe S, Suzuki T, Teramukai S, Uno K, Fukushima M. Cancer screening
using whole-body 18FDG-PET scan in healthy voluntary subjects. Proc ASCO 2004;23:535 (abstract #6072).
2. Ochiai K, Kuramoto H, Yamashita Y, Tanaka K, Tsukamoto N, Hiura M, Mizutani K, Hoshiai A, Teramukai S, Tada H. The impact of
therapeutic modalities on the outcome of advanced epitherial ovarian cancer patients treated in Japan. A JMTO study.Proc ASCO
2004;23:471 (abstract #5097).
3. Nishimura T, Tada H, Yokoyama N, Nakagawa M, Matsui S, Teramukai S, Fukushima M. Gefitinib-induced interstitial pneumonia in
Japan. - Problems in the approval process, pharmacovigilance and regulatory decision-making. Pharmacoepidem Dr S 2004;13:S120.
4. Teramukai S. Tumor down-staging as an endpoint for evaluating neoadjuvant chemotherapy in invasive bladder cancer. 2nd US-Japan
Biostatistics Workshop (Seattle). 2004.9.
|
2003年
|
1. Mohri K, Fukushima M. Water self organization through cyclotron resonance after application of μT, ULF magnetic field for long
range proton transport opening new bio-magnetics. SOMMA/KMS meeting 2003:Ar-15.
2. Mohri K, Fukushima M,Water molecule self-organization and proton transport triggered with milli-gauss, ULF AM magnetic field
cyclotron resonance. Intermag 2003:GB-09.
3. Tada H, Sasaki H, Teramukai S, for the Gynecological Lymphoedema Study Group. Para-aortic lymph node dissection as risk factors
related to the lower leg lymphedema after lymph node dissection in gynecological malignancies. Proc ASCO 2003;22:461
(abstract #1853).
4. Teramukai S, Nishiyama H, Tada H, Fukushima M, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Habuchi T Ogawa O. Identification of
subsets who will benefit from adjuvant chemotherapy in patients with invasive bladder cancer undergoing total cystectomy:
A retrospective study. Proc ASCO 2003;22:423 (abstract #1699).
5. Teramukai S, Matsuyama Y. Exploring between study heterogeneity in individual patient data meta-analysis. Control Clin
Trials 2003;24:113S-114S.
6. Teramukai S. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. 1st
US-Japan Biostatistics Workshop (Kobe). 2003.9.
|
2002年
|
1. Mohri K, Fukushima M, Matsumoto M. Gradual decrease of electric resistivity in water triggered with milli gauss low frequency
pulsed magnetic field. Intermag Europe 2002:FU-08.
2. Tada H, Kawahara M, Hosoe S, Furuse K, Tanio Y, Takenaka M, Hamada C, Fukushima M. A Preliminary Cost-Effectiveness Study of
Non-platinum Triplet Combination Chemotherapy in Stage IIIB/IV Non-Small Cell lung Cancer (NSCLC) Patients. Proc ASCO 2002;
21:235b (abstract#2757).
|
|
|
|
